Histone deacetylase class-I inhibition promotes epithelial gene expression in pancreatic cancer cells in a BRD4-and MYC-dependent manner

Nucleic Acids Research

Volumn 45, Issue 11, 2017, Pages 6334-6349

  Mishra, Vivek Kumar ^a   Wegwitz, Florian ^a   Kosinsky, Robyn Laura ^a   Sen, Madhobi ^a   Baumgartner, Roland ^b   Wulff, Tanja ^b   Siveke, Jens T ^c,d   Schildhaus, Hans Ulrich ^a   Najafova, Zeynab ^a   Kari, Vijayalakshmi ^a   Kohlhof, Hella ^b   Hessmann, Elisabeth ^a   Johnsen, Steven A ^a  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^b 4SC AG   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

4SC 202; BROMODOMAIN CONTAINING PROTEIN 4; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE INHIBITOR; MYC PROTEIN; PROTEIN; PROTEIN P21; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; 4SC-202; ANTINEOPLASTIC AGENT; BENZAMIDE DERIVATIVE; BRD4 PROTEIN, HUMAN; HDAC1 PROTEIN, HUMAN; MYC PROTEIN, HUMAN; NUCLEAR PROTEIN; TRANSCRIPTION FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CDKN1A GENE; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME INHIBITION; EPITHELIAL MESENCHYMAL TRANSITION; GENE; GENE EXPRESSION; GENETIC TRANSCRIPTION; GENOME-WIDE ASSOCIATION STUDY; HUMAN; HUMAN CELL; MOLECULAR MECHANICS; MOUSE; NONHUMAN; PANCREAS CANCER; PANCREATIC CANCER CELL LINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; TREATMENT DURATION; TUMOR DIFFERENTIATION; ANIMAL; DRUG EFFECTS; DRUG SCREENING; GENE EXPRESSION REGULATION; METABOLISM; NUDE MOUSE; PANCREAS CARCINOMA; PANCREAS TUMOR; PATHOLOGY; PHENOTYPE; PHYSIOLOGY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; BENZAMIDES; CARCINOMA, PANCREATIC DUCTAL; CELL LINE, TUMOR; CELL PROLIFERATION; EPITHELIAL-MESENCHYMAL TRANSITION; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE INHIBITORS; HUMANS; MICE, NUDE; NUCLEAR PROTEINS; PANCREATIC NEOPLASMS; PHENOTYPE; PROTO-ONCOGENE PROTEINS C-MYC; TRANSCRIPTION FACTORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85027026620     PISSN: 03051048     EISSN: 13624962     Source Type: Journal    
DOI: 10.1093/nar/gkx212     Document Type: Article

References (75)

1. Adiseshaiah,P.P., Crist,R.M., Hook,S.S. and McNeil,S.E. (2016) Nanomedicine strategies to overcome the pathophysiological barriers of pancreatic cancer. Nat. Rev. Clin. Oncol., 13, 750-765.
2. Jones,S., Zhang,X., Parsons,D.W., Lin,J.C.-H., Leary,R.J., Angenendt,P., Mankoo,P., Carter,H., Kamiyama,H., Jimeno,A. et al. (2008) Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science, 321, 1801-1806.
3. Hidalgo,M. (2010) Pancreatic cancer.N. Engl. J. Med., 362, 1605-1617.
4. Bailey,P., Chang,D.K., Nones,K., Johns,A.L., Patch,A.-M., Gingras,M.-C., Miller,D.K., Christ,A.N., Bruxner,T.J.C., Quinn,M.C. et al. (2016) Genomic analyses identify molecular subtypes of pancreatic cancer. Nature, 531, 47-52.
5. Shain,A.H., Salari,K., Giacomini,C.P. and Pollack,J.R. (2013) Integrative genomic and functional profiling of the pancreatic cancer genome. BMC Genomics, 14, 624.
6. Waddell,N., Pajic,M., Patch,A.-M., Chang,D.K., Kassahn,K.S., Bailey,P., Johns,A.L., Miller,D., Nones,K., Quek,K. et al. (2015) Whole genomes redefine the mutational landscape of pancreatic cancer. Nature, 518, 495-501.
7. Biankin,A.V.,Waddell,N., Kassahn,K.S., Gingras,M.-C., Muthuswamy,L.B., Johns,A.L., Miller,D.K., Wilson,P.J., Patch,A.-M., Wu,J. et al. (2012) Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature, 491, 399-405.
8. Witkiewicz,A.K.,McMillan,E.A., Balaji,U., Baek,G., Lin,W.-C., Mansour,J., Mollaee,M., Wagner,K.-U., Koduru,P., Yopp,A. et al. (2015) Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat. Commun., 6, 6744.
9. Hessmann,E., Johnsen,S.A., Siveke,J.T. and Ellenrieder,V. (2016) Epigenetic treatment of pancreatic cancer: is there a therapeutic perspective on the horizon? Gut, doi:10.1136/gutjnl-2016-312539.
10. Glozak,M.A. and Seto,E. (2007) Histone deacetylases and cancer. Oncogene, 26, 5420-5432.
11. Bolden,J.E., Peart,M.J. and Johnstone,R.W. (2006) Anticancer activities of histone deacetylase inhibitors. Nat. Rev. Drug Discov., 5, 769-784.
12. Damaskos,C., Karatzas,T., Nikolidakis,L., Kostakis,I.D., Karamaroudis,S., Boutsikos,G., Damaskou,Z., Kostakis,A. and Kouraklis,G. (2015) Histone deacetylase (HDAC) inhibitors: current evidence for therapeutic activities in pancreatic cancer. Anticancer Res., 35, 3129-3135.
13. Koutsounas,I., Giaginis,C. and Theocharis,S. (2013) Histone deacetylase inhibitors and pancreatic cancer: are there any promising clinical trials? World J. Gastroenterol. WJG, 19, 1173-1181.
14. Fritsche,P., Seidler,B., Schüler,S., Schnieke,A., Göttlicher,M., Schmid,R.M., Saur,D. and Schneider,G. (2009) HDAC2 mediates therapeutic resistance of pancreatic cancer cells via the BH3-only protein NOXA. Gut, 58, 1399-1409.
15. Schneider,G., Krämer,O.H., Fritsche,P., Schüler,S., Schmid,R.M. and Saur,D. (2010) Targeting histone deacetylases in pancreatic ductal adenocarcinoma. J. Cell. Mol. Med., 14, 1255-1263.
16. Marks,P.A., Rifkind,R.A., Richon,V.M., Breslow,R., Miller,T. and Kelly,W.K. (2001) Histone deacetylases and cancer: causes and therapies. Nat. Rev. Cancer, 1, 194-202.
17. Wang,G., He,J., Zhao,J., Yun,W., Xie,C., Taub,J.W., Azmi,A., Mohammad,R.M., Dong,Y., Kong,W. et al. (2012) Class I and class II histone deacetylases are potential therapeutic targets for treating pancreatic cancer. PLoS ONE, 7, e52095.
18. Schüler,S., Fritsche,P., Diersch,S., Arlt,A., Schmid,R.M., Saur,D. and Schneider,G. (2010) HDAC2 attenuates TRAIL-induced apoptosis of pancreatic cancer cells. Mol. Cancer, 9, 80.
19. Filippakopoulos,P., Picaud,S., Mangos,M., Keates,T., Lambert,J.-P., Barsyte-Lovejoy,D., Felletar,I., Volkmer,R., Müller,S., Pawson,T. et al. (2012) Histone recognition and large-scale structural analysis of the human bromodomain family. Cell, 149, 214-231.
20. Filippakopoulos,P., Qi,J., Picaud,S., Shen,Y., Smith,W.B., Fedorov,O., Morse,E.M., Keates,T., Hickman,T.T., Felletar,I. et al. (2010) Selective inhibition of BET bromodomains. Nature, 468, 1067-1073.
21. Nicodeme,E., Jeffrey,K.L., Schaefer,U., Beinke,S., Dewell,S., Chung,C., Chandwani,R., Marazzi,I., Wilson,P., Coste,H. et al. (2010) Suppression of inflammation by a synthetic histone mimic. Nature, 468, 1119-1123.
22. Zuber,J., Shi,J., Wang,E., Rappaport,A.R., Herrmann,H., Sison,E.A., Magoon,D., Qi,J., Blatt,K., Wunderlich,M. et al. (2011) RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature, 478, 524-528.
23. Dawson,M.A., Prinjha,R.K., Dittmann,A., Giotopoulos,G., Bantscheff,M., Chan,W.-I., Robson,S.C., Chung,C., Hopf,C., Savitski,M.M. et al. (2011) Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature, 478, 529-533.
24. Delmore,J.E., Issa,G.C., Lemieux,M.E., Rahl,P.B., Shi,J., Jacobs,H.M., Kastritis,E., Gilpatrick,T., Paranal,R.M., Qi,J. et al. (2011) BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell, 146, 904-917.
25. Puissant,A., Frumm,S.M., Alexe,G., Bassil,C.F., Qi,J., Chanthery,Y.H., Nekritz,E.A., Zeid,R., Gustafson,W.C., Greninger,P. et al. (2013) Targeting MYCN in neuroblastoma by BET bromodomain inhibition. Cancer Discov., 3, 308-323.
26. Asangani,I.A., Dommeti,V.L., Wang,X., Malik,R., Cieslik,M., Yang,R., Escara-Wilke,J., Wilder-Romans,K., Dhanireddy,S., Engelke,C. et al. (2014) Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer. Nature, 510, 278-282.
27. Coudé,M.-M., Braun,T., Berrou,J., Dupont,M., Bertrand,S., Masse,A., Raffoux,E., Itzykson,R., Delord,M., Riveiro,M.E. et al. (2015) BET inhibitor OTX015 targets BRD2 and BRD4 and decreases c-MYC in acute leukemia cells. Oncotarget, 6, 17698-17712.
28. Nagarajan,S., Hossan,T., Alawi,M., Najafova,Z., Indenbirken,D., Bedi,U., Taipaleenmäki,H., Ben-Batalla,I., Scheller,M., Loges,S. et al. (2014) Bromodomain protein BRD4 is required for estrogen receptor-dependent enhancer activation and gene transcription. Cell Rep., 8, 460-469.
29. Nagarajan,S., Bedi,U., Budida,A., Hamdan,F.H., Mishra,V.K., Najafova,Z., Xie,W., Alawi,M., Indenbirken,D., Knapp,S. et al. BRD4 promotes p63 and GRHL3 expression downstream of FOXO in mammary epithelial cells. Nucleic Acids Res., doi:10.1093/nar/gkw1276.
30. Najafova,Z., Tirado-Magallanes,R., Subramaniam,M., Hossan,T., Schmidt,G., Nagarajan,S., Baumgart,S.J., Mishra,V.K., Bedi,U., Hesse,E. et al. (2016) BRD4 localization to lineage-specific enhancers is associated with a distinct transcription factor repertoire. Nucleic Acids Res., doi:10.1093/nar/gkw826.
31. Mazur,P.K., Herner,A., Mello,S.S., Wirth,M., Hausmann,S., Sánchez-Rivera,F.J., Lofgren,S.M., Kuschma,T., Hahn,S.A., Vangala,D. et al. (2015) Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma. Nat. Med., 21, 1163-1171.
32. Prenzel,T., Begus-Nahrmann,Y., Kramer,F., Hennion,M., Hsu,C., Gorsler,T., Hintermair,C., Eick,D., Kremmer,E., Simons,M. et al. (2011) Estrogen-dependent gene transcription in human breast cancer cells relies upon proteasome-dependent monoubiquitination of histone H2B. Cancer Res., 71, 5739-5753.
33. Mishra,V.K., Subramaniam,M., Kari,V., Pitel,K.S., Baumgart,S.J., Naylor,R.M., Nagarajan,S.,Wegwitz,F., Ellenrieder,V., Hawse,J.R. et al. (2017) Krüppel-like transcription factor KLF10 suppresses TGFκ-induced epithelial-to-mesenchymal transition via a negative feedback mechanism. Cancer Res., doi:10.1158/0008-5472.CAN-16-2589.
34. Schneider,C.A., Rasband,W.S. and Eliceiri,K.W. (2012) NIH image to ImageJ: 25 years of image analysis. Nat. Methods, 9, 671-675.
35. Singh,S.K., Chen,N.-M., Hessmann,E., Siveke,J., Lahmann,M., Singh,G., Voelker,N., Vogt,S., Esposito,I., Schmidt,A. et al. (2015) Antithetical NFATc1-Sox2 and p53-miR200 signaling networks govern pancreatic cancer cell plasticity. EMBO J., 34, 517-530.
36. Babraham bioinformatics-FastQC a quality control tool for high throughput sequence data.
37. Langmead,B. and Salzberg,S.L. (2012) Fast gapped-read alignment with Bowtie 2. Nat. Methods, 9, 357-359.
38. Zhang,Y., Liu,T., Meyer,C.A., Eeckhoute,J., Johnson,D.S., Bernstein,B.E., Nusbaum,C., Myers,R.M., Brown,M., Li,W. et al. (2008) Model-based analysis of ChIP-Seq (MACS). Genome Biol., 9, R137.
39. Ramirez,F., Dündar,F., Diehl,S., Grüning,B.A. and Manke,T. (2014) deepTools: a flexible platform for exploring deep-sequencing data. Nucleic Acids Res., 42, W187-W191.
40. Robinson,J.T., Thorvaldsdóttir,H.,Winckler,W., Guttman,M., Lander,E.S., Getz,G. and Mesirov,J.P. (2011) Integrative genomics viewer. Nat. Biotechnol., 29, 24-26.
41. Ross-Innes,C.S., Stark,R., Teschendorff,A.E., Holmes,K.A., Ali,H.R., Dunning,M.J., Brown,G.D., Gojis,O., Ellis,I.O., Green,A.R. et al. (2012) Differential oestrogen receptor binding is associated with clinical outcome in breast cancer. Nature, 481, 389-393.
42. McLean,C.Y., Bristor,D., Hiller,M., Clarke,S.L., Schaar,B.T., Lowe,C.B., Wenger,A.M. and Bejerano,G. (2010) GREAT improves functional interpretation of cis-regulatory regions. Nat. Biotechnol., 28, 495-501.
43. Griffon,A. Barbier,Q., Dalino,J., van Helden,J., Spicuglia,S. and Ballester,B. (2014) Integrative analysis of public ChIP-seq experiments reveals a complex multi-cell regulatory landscape. Nucleic Acids Res., doi:10.1093/nar/gku1280.
44. Anders,S., Pyl,P.T. and Huber,W. (2015) HTSeq-A Python framework to work with high-throughput sequencing data. Bioinformatics, 31, 166-169.
45. Love,M.I., Huber,W. and Anders,S. (2014) Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol., 15, 550.
46. Pinkerneil,M., Hoffmann,M.J., Kohlhof,H., Schulz,W.A. and Niegisch,G. (2016) Evaluation of the therapeutic potential of the novel isotype specific HDAC inhibitor 4SC-202 in urothelial carcinoma cell lines. Target. Oncol., 11, 783-798.
47. Richon,V.M., Sandhoff,T.W., Rifkind,R.A. and Marks,P.A. (2000) Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc. Natl. Acad. Sci. U.S.A., 97, 10014-10019.
48. Muscat,A., Popovski,D., Jayasekara,W.S.N., Rossello,F.J., Ferguson,M., Marini,K.D., Alamgeer,M., Algar,E.M., Downie,P., Watkins,D.N. et al. (2016) Low-dose histone deacetylase inhibitor treatment leads to tumor growth arrest and multi-lineage differentiation of malignant rhabdoid tumors. Clin. Cancer Res., 22, 3560-3570.
49. Munster,P.N., Troso-Sandoval,T., Rosen,N., Rifkind,R., Marks,P.A. and Richon,V.M. (2001) The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells. Cancer Res., 61, 8492-8497.
50. Lubeseder-Martellato,C., Hidalgo-Sastre,A., Hartmann,C., Alexandrow,K., Kamyabi-Moghaddam,Z., Sipos,B., Wirth,M., Neff,F., Reichert,M., Heid,I. et al. (2014) Membranous CD24 drives the epithelial phenotype of pancreatic cancer. Oncotarget, doi:10.18632/oncotarget.9402.
51. Visvader,J.E. and Lindeman,G.J. (2008) Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat. Rev. Cancer, 8, 755-768.
52. Ellenrieder,V., Hendler,S.F., Boeck,W., Seufferlein,T., Menke,A., Ruhland,C., Adler,G. and Gress,T.M. (2001) Transforming growth factor 1 treatment leads to an epithelial-mesenchymal transdifferentiation of pancreatic cancer cells requiring extracellular signal-regulated kinase 2 activation. Cancer Res., 61, 4222-4228.
53. Hong,S.-M., Li,A., Olino,K., Wolfgang,C.L., Herman,J.M., Schulick,R.D., Iacobuzio-Donahue,C., Hruban,R.H. and Goggins,M. (2011) Loss of E-cadherin expression and outcome among patients with resectable pancreatic adenocarcinomas. Mod. Pathol., 24, 1237-1247.
54. Georgiadis,A., Tschernutter,M., Bainbridge,J.W.B., Balaggan,K.S., Mowat,F., West,E.L., Munro,P.M.G., Thrasher,A.J., Matter,K., Balda,M.S. et al. (2010) The tight junction associated signalling proteins ZO-1 and ZONAB regulate retinal pigment epithelium homeostasis in mice. PLoS ONE, 5, e15730.
55. Ni,S., Xu,L., Huang,J., Feng,J., Zhu,H., Wang,G. and Wang,X. (2013) Increased ZO-1 expression predicts valuable prognosis in non-small cell lung cancer. Int. J. Clin. Exp. Pathol., 6, 2887-2895.
56. Orbán,E., Szabó,E., Lotz,G., Kupcsulik,P., Páska,C., Schaff,Z. and Kiss,A. (2008) Different expression of occludin and ZO-1 in primary and metastatic liver tumors. Pathol. Oncol. Res., 14, 299-306.
57. Katz,J.P., Perreault,N., Goldstein,B.G., Lee,C.S., Labosky,P.A., Yang,V.W. and Kaestner,K.H. (2002) The zinc-finger transcription factor Klf4 is required for terminal differentiation of goblet cells in the colon. Development, 129, 2619-2628.
58. Morris,V.A., Cummings,C.L., Korb,B., Boaglio,S. and Oehler,V.G. (2016) Deregulated KLF4 expression in myeloid leukemias alters cell proliferation and differentiation through microRNA and gene targets. Mol. Cell. Biol., 36, 559-573.
59. Langbein,L., Eckhart,L., Rogers,M.A., Praetzel-Wunder,S. and Schweizer,J. (2010) Against the rules: human Keratin K80: two functional alternative splice variants, K80 AND K80.1, with special cellular localization in a wide range of epithelia. J. Biol. Chem., 285, 36909-36921.
60. Hahn,S.A., Schutte,M., Hoque,A.T.M.S., Moskaluk,C.A., Costa,L.T. da, Rozenblum,E.,Weinstein,C.L., Fischer,A., Yeo,C.J., Hruban,R.H. et al. (1996) DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science, 271, 350-353.
61. Arumugam,T., Ramachandran,V., Fournier,K.F., Wang,H., Marquis,L., Abbruzzese,J.L., Gallick,G.E., Logsdon,C.D., McConkey,D.J. and Choi,W. (2009) Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. Cancer Res., 69, 5820-5828.
62. Shah,A.N., Summy,J.M., Zhang,J., Park,S.I., Parikh,N.U. and Gallick,G.E. (2007) Development and characterization of gemcitabine-resistant pancreatic tumor cells. Ann. Surg. Oncol., 14, 3629-3637.
63. Bachem,M.G., Schünemann,M., Ramadani,M., Siech,M., Beger,H., Buck,A., Zhou,S., Schmid-Kotsas,A. and Adler,G. (2005) Pancreatic carcinoma cells induce fibrosis by stimulating proliferation and matrix synthesis of stellate cells. Gastroenterology, 128, 907-921.
64. Löhr,M., Schmidt,C., Ringel,J., Kluth,M., Müller,P., Nizze,H. and Jesnowski,R. (2001) Transforming growth factor-β1 induces desmoplasia in an experimental model of human pancreatic carcinoma. Cancer Res., 61, 550-555.
65. Meidhof,S., Brabletz,S., Lehmann,W., Preca,B.-T., Mock,K., Ruh,M., Schüler,J., Berthold,M., Weber,A., Burk,U. et al. (2015) ZEB1-associated drug resistance in cancer cells is reversed by the class I HDAC inhibitor mocetinostat. EMBO Mol. Med., 7, 831-847.
66. Aghdassi,A., Sendler,M., Guenther,A., Mayerle,J., Behn,C.-O., Heidecke,C.-D., Friess,H., Büchler,M., Evert,M., Lerch,M.M. et al. (2012) Recruitment of histone deacetylases HDAC1 and HDAC2 by the transcriptional repressor ZEB1 downregulates E-cadherin expression in pancreatic cancer. Gut, 61, 439-448.
67. Kanno,T., Kanno,Y., LeRoy,G., Campos,E., Sun,H.-W., Brooks,S.R., Vahedi,G., Heightman,T.D., Garcia,B.A., Reinberg,D. et al. (2014) BRD4 assists elongation of both coding and enhancer RNAs by interacting with acetylated histones. Nat. Struct. Mol. Biol., 21, 1047-1057.
68. Kanno,T., Kanno,Y., Siegel,R.M., Jang,M.K., Lenardo,M.J. and Ozato,K. (2004) Selective recognition of acetylated histones by bromodomain proteins visualized in living cells. Mol. Cell, 13, 33-43.
69. Jang,M.K., Mochizuki,K., Zhou,M., Jeong,H.-S., Brady,J.N. and Ozato,K. (2005) The bromodomain protein Brd4 Is a positive regulatory component of P-TEFb and stimulates RNA polymerase II-dependent transcription. Mol. Cell, 19, 523-534.
70. Berta,M.A., Baker,C.M., Cottle,D.L. and Watt,F.M. (2009) Dose and context dependent effects of Myc on epidermal stem cell proliferation and differentiation. EMBO Mol. Med., 2, 16-25.
71. Watt,F.M., Frye,M. and Benitah,S.A. (2008) MYC in mammalian epidermis: how can an oncogene stimulate differentiation? Nat. Rev. Cancer, 8, 234-242.
72. Berger,P.L., Frank,S.B., Schulz,V.V., Nollet,E.A., Edick,M.J., Holly,B., Chang,T.-T.A., Hostetter,G., Kim,S. and Miranti,C.K. (2014) Transient induction of ING4 by Myc drives prostate epithelial cell differentiation and its disruption drives prostate tumorigenesis. Cancer Res., 74, 3357-3368.
73. Greer,C.B., Tanaka,Y., Kim,Y.J., Xie,P., Zhang,M.Q., Park,I.-H. and Kim,T.H. (2015) Histone deacetylases positively regulate transcription through the elongation machinery. Cell Rep., 13, 1444-1455.
74. Bian,B., Bigonnet,M., Gayet,O., Loncle,C., Maignan,A., Gilabert,M., Moutardier,V., Garcia,S., Turrini,O., Delpero,J.-R. et al. (2017) Gene expression profiling of patient-derived pancreatic cancer xenografts predicts sensitivity to the BET bromodomain inhibitor JQ1: implications for individualized medicine efforts. EMBO Mol. Med., doi:10.15252/emmm.201606975.
75. Garcia,P.L., Miller,A.L., Kreitzburg,K.M., Council,L.N., Gamblin,T.L., Christein,J.D., Heslin,M.J., Arnoletti,J.P., Richardson,J.H., Chen,D. et al. (2016) The BET bromodomain inhibitor JQ1 suppresses growth of pancreatic ductal adenocarcinoma in patient-derived xenograft models. Oncogene, 35, 833-845.